84 related articles for article (PubMed ID: 21910718)
1. Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.
Kassam S; Juliger S; Jia L; Joel SP
Br J Haematol; 2012 Jan; 156(2):286-9. PubMed ID: 21910718
[No Abstract] [Full Text] [Related]
2. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Orciuolo E; Buda G; Pelosini M; Petrini M
Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
[No Abstract] [Full Text] [Related]
6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
8. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Jung HJ; Chen Z; McCarty N
Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
[TBL] [Abstract][Full Text] [Related]
10. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Paoluzzi L; Scotto L; Marchi E; Seshan VE; O'Connor OA
Br J Haematol; 2009 Sep; 146(6):656-9. PubMed ID: 19604235
[TBL] [Abstract][Full Text] [Related]
11. Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Weinkauf M; Hutter G; Zimmermann Y; Hartmann E; Rosenwald A; Dreyling M
Talanta; 2010 Feb; 80(4):1539-44. PubMed ID: 20082812
[TBL] [Abstract][Full Text] [Related]
12. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
14. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Michopoulos S; Petraki K; Matsouka C; Kastritis E; Chrysanthopoulou H; Dimopoulos MA
J Clin Oncol; 2008 Mar; 26(9):1555-7. PubMed ID: 18349408
[No Abstract] [Full Text] [Related]
15. Bortezomib-based therapy for mantle-cell lymphoma.
Sengar M; Jain H
N Engl J Med; 2015 Jun; 372(23):2270-1. PubMed ID: 26039614
[No Abstract] [Full Text] [Related]
16. Bortezomib-based therapy for mantle-cell lymphoma.
Baccarani M
N Engl J Med; 2015 Jun; 372(23):2270. PubMed ID: 26039613
[No Abstract] [Full Text] [Related]
17. Bortezomib-based therapy for mantle-cell lymphoma.
Cavalli F
N Engl J Med; 2015 Jun; 372(23):2271. PubMed ID: 26039612
[No Abstract] [Full Text] [Related]
18. [Right cervical lymph node enlargement].
Xie JL; Zhou XG; Wang ZQ
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):273-4. PubMed ID: 23928539
[No Abstract] [Full Text] [Related]
19. Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Rolland D; Raharijaona M; Barbarat A; Houlgatte R; Thieblemont C
Anticancer Res; 2010 Oct; 30(10):3951-7. PubMed ID: 21036708
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
